Nirmatrelvir/ritonavir
Aliases
Nirmatrelvir/ritonavir commercial tablets, Paxlovid
10 clinical trials
1 product
3 abstracts
20 indications
Indication
Post COVID-19 ConditionIndication
UnspecifiedIndication
COVID-19Indication
Biological AvailabilityIndication
Healthy ParticipantsIndication
Chronic Kidney Disease stage 4Indication
Chronic Kidney Disease Stage 5Indication
Chronic Kidney DiseaseIndication
ChronicIndication
Post-COVID-19 SyndromeIndication
Long COVIDIndication
Long Covid-19Indication
Post-COVID SyndromeIndication
postinfectious inflammationIndication
Postinfectious DisorderIndication
Cardiac surgeryIndication
SARSIndication
Community-acquired PneumoniaIndication
InfluenzaAbstract
Safety and acceptance of nirmatrelvir/ritonavir in early SARS-CoV-2 treatment in Greek patients with solid cancer.Org: HeSMO,
Clinical trial
PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in NorwayStatus: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
Post-marketing Surveillance Study of the Effectiveness and Safety of New Oral Antivirals for Outpatients With Mild-moderate COVID-19Status: Active (not recruiting), Estimated PCD: 2024-01-31
Clinical trial
A PHASE 1, OPEN-LABEL, RANDOMIZED, SINGLE DOSE, CROSSOVER STUDY TO DETERMINE THE BE OF NIRMATRELVIR FOLLOWING ORAL ADMINISTRATION OF FDC TABLETS RELATIVE TO THE PAXLOVID® COMMERCIAL TABLETS IN HEALTHY ADULT PARTICIPANTS UNDER FASTED CONDITIONSStatus: Not yet recruiting, Estimated PCD: 2025-06-10
Clinical trial
Safety and Clinical and Virologic Outcomes in COVID-19 Patients With Chronic Kidney Disease Treated With Nirmatrelvir-ritonavirStatus: Completed, Estimated PCD: 2023-01-31
Clinical trial
Efficiency and Safety of Paxlovid for the Treatment of COVID-19 Patients With Severe Chronic Kidney DiseaseStatus: Recruiting, Estimated PCD: 2025-05-30
Clinical trial
An Interventional, Double-Blinded, 2-Arm Study to Investigate the Efficacy of Orally Administered Nirmatrelvir/Ritonavir Compared With Placebo/Ritonavir in Non-hospitalized Adult Participants Suffering From Post-COVIDStatus: Recruiting, Estimated PCD: 2024-01-31
Clinical trial
Prophylactic Effect of Nirmatrelvir/Ritonavir and Ursodeoxycholic Acid on Reducing Complications After Cardiac Surgery During COVID-19 Pandemics: A Prospective, Randomized Controlled, Multicenter TrialStatus: Active (not recruiting), Estimated PCD: 2023-03-24
Clinical trial
Randomised Evaluation of COVID-19 TherapyStatus: Recruiting, Estimated PCD: 2026-06-30
Clinical trial
Canadian Adaptive Platform Trial of Treatments for COVID-19 in Community SettingsStatus: Recruiting, Estimated PCD: 2024-01-01
Clinical trial
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaStatus: Recruiting, Estimated PCD: 2026-02-01
Abstract
Safety and PK (pharmacokinetic) profile of niraparib (nir) + dostarlimab (dost) in pediatric patients (pts) with recurrent or refractory (RR) solid tumors: SCOOP study.Org: Institut Curie, Saint Cloud, France, University of Paris-Saclay, Hôpital Pour Enfants De La Timone, Hospital Universitario 12 de Octubre, Hospital U i P La Fe,
Abstract
Real-world effectiveness of prophylactic tixagevimab-cilgavimab monoclonal antibodies on incidence and severity of COVID-19 infection in patients with cancer.Org: University of Massachusetts Chan Medical School, Baystate Health, Springfield, MA,
Product
Nirmatrelvir/ritonavir